Nuvectis Pharma reported positive Phase 1b trial results for NXP200, a second-generation BRAF inhibitor, in 27 patients with recurrent or progressive BRAF V600-mutated gliomas. The drug achieved an objective response rate of 40% in high-grade and 42.9% in low-grade gliomas, including complete responses and deep tumor reductions. NXP200 also showed activity in patients previously treated with BRAF inhibitors and had a manageable safety profile with no treatment-related discontinuations or deaths. The company plans to submit a U.S. IND for NXP200 by the end of 2026, aiming to develop it as a best-in-class treatment for these brain tumors.
Nuvectis Pharma's positive Phase 1b trial results for NXP200 provide context for healthcare sector interest. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 26, 2026 19:02 WIB: out of 150 priced US health stocks, 78 rose and 48 fell. Notable movers include WGS at USD 57.50 (+2.40%), NVS at USD 153.99 (+1.90%), and ALMS at USD 6.90 (+1.77%).
Smithfield Foods has created a $250,000 Future Leaders Scholarship program at Christopher Newport University to support eight incoming business students with $7,500 annual scholarships renewable for up to four years. The program aims to help local st...
E-Power Inc.'s joint venture, Sunrise Guizhou, received RMB 110 million of a planned RMB 200 million capital increase, raising its registered capital and valuing the company at RMB 2 billion post-money. The funds will support business expansion, R&D,...
AS Tallinna Sadam has signed a €50 million unsecured loan agreement with Swedbank, with a 5-year term and interest based on 3-month Euribor plus a margin. The loan will be fully drawn on October 26, 2026, and matures on October 26, 2031. This financi...
AS Tallinna Sadam signed a €50 million unsecured loan agreement with AS Swedbank, maturing in five years with an interest rate based on 3-month Euribor plus margin. The loan, drawn on October 26, 2026, will be used to redeem bonds worth €50.4 million...
Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...
